There are more than 300 million people in China living with allergy diseases and tens of millions of people suffering from autoimmune diseases. Prior to the establishment of HOB, the hospitals and labs are largely relied on diagnostic products imported from Europe and the United States. Many doctors and patients urgently needed high-quality yet cost-effective products for in vitro diagnosis of allergy and autoimmune diseases.

HOB, through dedicated research investment, has gradually become in China the market leader in allergy diagnostics and a rising star in autoimmune diagnostics. HOB has been competing against well-known and market-dominating American and European companies through intensive R&D investment and consistent high-quality as well as cost-conscious manufacturing. We have mastered core technologies and provided comprehensive product lines that meet customers’ various needs.

“Innovation” is one of our core competitiveness. We are one of the few companies worldwide that has developed and successfully launched fully automated chemiluminescence platforms for allergy and autoimmune in vitro diagnostics. With the advanced technology, HOB is leading allergy and autoimmune diseases in vitro diagnostics into a new era in China. Meanwhile, we are fully leveraging the first-mover advantage to participate in the international market and striving to become a top-tier brand in allergy and autoimmune in vitro diagnostics.

With the deepening reformation of Chinese national medical system and emerging friendly policies, we firmly believe that HOB and other domestic in vitro diagnostic companies with core technologies will surely greet new opportunities. We are committed to “creating a global top-tier allergy and autoimmune diagnostic brand, building a world first-class IVD company".